The Shive Laboratory studies the tumor suppressor genes BRCA2 and TP53, which are linked to significant cancer susceptibility in humans. We use the zebrafish model to identify conserved genetic and molecular factors that contribute to cancer development in the context of heritable BRCA2 and TP53 mutations.
The zebrafish model provides a powerful in vivo tool for comparative cancer research. Despite millions of years of evolutionary distance separating humans and zebrafish, numerous studies have demonstrated that key genes implicated in human cancer also drive cancer development in zebrafish. Such studies have provided novel insight into conserved molecular pathways that contribute to cancer onset, progression, and metastasis, and have identified novel molecular targets for therapeutic intervention. Multiple advantages of the zebrafish model facilitate these studies, such as high fecundity and short generation time; high-throughput, cost-effective chemical screening; ease of genetic manipulation; and xenotransplantation without immune suppression.
Highly motivated undergraduate students, graduate students, and postdoctoral fellows interested in our research are encouraged to contact Dr. Shive regarding open positions.